- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00483301
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The primary objective of this phase II multicenter trial is to:
Measure the response rate (RR) of this combination and schedule in patients with metastatic melanoma
The secondary objectives are to:
Assess the safety and toxicity of this regimen in this patient population
Determine the 1-year and median PFS of patients treated according to protocol
Determine overall survival (OS)
STUDY DESIGN
This will be a Phase II study single arm study with a two-stage design with a maximum sample size of 43 patients, 18 in the first stage and 25 in the second stage.
Study duration: A minimum yearly accrual of 10-15 patients/institution is expected. Therefore, to reach the first stage, the study will take 1.2 to 1.8 years with one institution, 0.6 to 0.9 years with 2 institutions, and 0.4 to 0.6 years with 3. If the study continues to full accrual to 43 patients, completion will take 2.9 to 4.3 years with one institution, 1.4 to 2.2 years with two and 0.96 to 1.43 years with three institutions.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90025
- Dr. Steven O'Day
-
-
Florida
-
Miami Beach, Florida, Forente stater, 33140
- Mt. Sinai Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed diagnosis of melanoma with measurable disease
- Patients with stage IV, previously untreated, refractory to initial therapy or progressing after response to initial therapy
- Patients with unresectable stage III, including unresectable in-transit metastases
- Two prior chemotherapy regimen is allowed
- One prior immunotherapy regimen is allowed
- No other concurrent investigational therapy
- Radiation therapy to non-target lesions or to one of multiple target lesions may be allowed on a case-by-case basis
- Patients must be past the nadir from previous cytotoxic therapy
- Age at least 18 years
- ECOG performance status 0-2
- Hemoglobin > 9.0 g/dl, absolute neutrophil count (ANC) > 1,500/mm3, platelet count > 100,000/mm3
- Total bilirubin within normal limits, ALT and AST < 2.0 x the ULN ( < 5 x ULN for patients with liver involvement), INR < 1.5 and aPTT within normal limits. Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care.
- Creatinine < 1.5 x ULN, serum calcium within normal limits
- Patients with stable brain metastasis who have been treated with either whole brain radiation or Gamma Knife and have been off steroids for > 4 weeks
- Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.
- Ability to understand and sign a written informed consent document. All patients must have a signed informed consent before registration and initiation of therapy
Exclusion Criteria:
- Cardiac disease: Congestive heart failure > class II NYHA.
- Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.
- No known severe hypersensitivity or suspected allergy to sorafenib, ABI-007 or any of the excipients
- Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude progressing brain metastasis.
- Peripheral neuropathy greater than grade II
- Serious intercurrent medical or psychiatric illness, including serious active infection
- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
- Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.
- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.
- Serious non-healing wound, ulcer, or bone fracture.
- Evidence or history of bleeding diathesis or coagulopathy
- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.
- Use of St. John's Wort or rifampin (rifampicin)
- Any condition that impairs patient's ability to swallow whole pills.
- Any malabsorption problem
- No treatment for melanoma within the previous 4 weeks.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Primary Objective
Tidsramme: one - two years
|
Measure the response rate (RR) of this combination and schedule in patients with metastatic melanoma
|
one - two years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Secondary Objective
Tidsramme: one-two years
|
3.2.1 Assess the safety and toxicity of this regimen in this patient population Determine the 1-year and median PFS of patients treated according to protocol Determine overall survival (OS)
|
one-two years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Jose Lutzky, Physician, Mt. Sinai Medical Center Miami Beach Florida
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Nevroendokrine svulster
- Nevi og melanomer
- Melanom
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Proteinkinasehemmere
- Sorafenib
- Albuminbundet paklitaksel
Andre studie-ID-numre
- MEL0205
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ondartet melanom
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RekrutteringMetastatisk melanom | Konjunktivalt melanom | Okulært melanom | Uopererbart melanom | Uveal melanom | Kutant melanom | Slimhinne melanom | Iris melanom | Akralt melanom | Ikke-kutant melanomForente stater
-
MelanomaPRO, RussiaRekrutteringMelanom | Melanom (hud) | Melanom stadium IV | Melanom stadium III | Melanom, stadium II | Melanom, Uveal | Melanom in situ | Melanom, okulærDen russiske føderasjonen
-
National Cancer Institute (NCI)FullførtTilbakevendende melanom | Stadium IIIA melanom | Stadium IIIB melanom | Stage IIIC melanom | Stage IIB melanom | Stage IIC melanom | Stadium IA melanom | Stage IB melanom | Stage IIA melanomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI)FullførtTilbakevendende melanom | Stage IV melanom | Slimhinne melanom | Ciliary Body og Choroid Melanom, Medium/Large Størrelse | Ciliary Body og Choroid Melanom, liten størrelse | Iris melanom | Metastatisk intraokulært melanom | Tilbakevendende intraokulært melanom | Stage IV Intraokulært melanom | Stadium IIIA... og andre forholdForente stater
-
National Cancer Institute (NCI)FullførtStage IV melanom | Ciliary Body og Choroid Melanom, Medium/Large Størrelse | Iris melanom | Stadium IIIA melanom | Stadium IIIB melanom | Stage IIIC melanom | Ekstraokulært ekstensjonsmelanom | Stage IIB melanom | Stage IIC melanomForente stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkAvsluttetTilbakevendende melanom | Stage IV melanom | Metastatisk intraokulært melanom | Tilbakevendende intraokulært melanom | Stage IV Intraokulært melanom | Stadium IIIA melanom | Stadium IIIB melanom | Stage IIIC melanom | Ekstraokulært ekstensjonsmelanom | Stadium IIIA Intraokulært melanom | Stadium IIIB Intraokulært... og andre forholdForente stater
-
BiocadRekrutteringMelanom | Melanom (hud) | Melanom stadium IV | Melanom stadium III | Melanom Metastatisk | Melanom uoperabelt | Melanom avansertIndia, Den russiske føderasjonen, Hviterussland
-
Mayo ClinicNational Cancer Institute (NCI)FullførtTilbakevendende melanom | Stage IV melanom | Stadium IIIA melanom | Stadium IIIB melanom | Stage IIIC melanom | Stage IIB melanom | Stage IIC melanom | Stage IIA melanomForente stater
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RekrutteringUopererbart melanom | Klinisk stadium III kutant melanom AJCC v8 | Melanom hos ukjent primær | Patologisk stadium IIIB kutant melanom AJCC v8 | Patologisk stadium IIIC kutant melanom AJCC v8 | Patologisk stadium IIID kutant melanom AJCC v8 | Klinisk stadium IV kutant melanom AJCC v8 | Patologisk stadium... og andre forholdForente stater
-
National Cancer Institute (NCI)FullførtTilbakevendende melanom | Stage IV melanom | Stadium IIIA melanom | Stadium IIIB melanom | Stage IIIC melanom | Akralt lentiginøst malignt melanomForente stater
Kliniske studier på Sorafenib (BAY 43-9006)
-
National Cancer Institute (NCI)FullførtAkutt myeloid leukemi med FLT3/ITD-mutasjonForente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeSkrumplever | Hepatitt B-infeksjon | Tilbakevendende ondartet fast neoplasma | Metastatisk malignt fast neoplasma | Ikke-opererbar fast neoplasma | Tilbakevendende hepatocellulært karsinom | Refraktær ondartet neoplasma | Hepatitt C-infeksjon | Stage IV hepatocellulært karsinom AJCC v7Forente stater
-
National Cancer Institute (NCI)FullførtNevroendokrin svulst | Gastrinom | Glukagonom | Insulinom | Metastatisk gastrointestinal karsinoid svulst | Pankreatisk polypeptidsvulst | Tilbakevendende gastrointestinal karsinoid svulst | Tilbakevendende øycellekarsinom | Somatostatinom | WDHA syndromForente stater
-
National Cancer Institute (NCI)AvsluttetRefraktær kronisk lymfatisk leukemi | Stadium I Kronisk lymfatisk leukemi | Stadium II Kronisk lymfatisk leukemi | Stadium III Kronisk lymfatisk leukemi | Stadium IV Kronisk lymfatisk leukemiForente stater
-
National Cancer Institute (NCI)FullførtMetastatisk overgangscellekreft i nyrebekkenet og urinlederen | Tilbakevendende blærekreft | Tilbakevendende overgangscellekreft i nyrebekkenet og urinlederen | Regional overgangscellekreft i nyrebekkenet og urinlederen | Stadium III blærekreft | Stadium IV blærekreft | Overgangscellekarsinom i blærenCanada
-
National Cancer Institute (NCI)FullførtStadium IIIB Ikke-småcellet lungekreft | Tilbakevendende ikke-småcellet lungekreft | Stadium IV Ikke-småcellet lungekreftForente stater
-
National Cancer Institute (NCI)FullførtUterin karsinosarkom | Ovarialt sarkom | Tilbakevendende bløtvevssarkom hos voksne | Tilbakevendende livmorsarkom | Stage III Bløtvevssarkom for voksne | Stadium III livmorsarkom | Stage IV Bløtvevssarkom for voksne | Stadium IV livmorsarkom | Angiosarkom hos voksne | Voksen epiteloid sarkom | Leiomyosarkom hos... og andre forholdForente stater
-
National Cancer Institute (NCI)FullførtTilbakevendende ekstrahepatisk gallekanalkreft | Tilbakevendende galleblærenkreft | Ikke-opererbar ekstrahepatisk gallekanalkreft | Ikke-opererbar galleblærekreft | Kolangiokarsinom i den ekstrahepatiske gallekanalen | Kolangiokarsinom i galleblæren | Adenokarsinom i galleblæren | Adenokarsinom med plateepitelmetaplasi... og andre forholdForente stater
-
National Cancer Institute (NCI)FullførtUterin karsinosarkom | Tilbakevendende livmorsarkom | Stadium III livmorsarkom | Stadium IV livmorsarkomForente stater, Canada
-
National Cancer Institute (NCI)FullførtTilbakevendende voksent diffust storcellet lymfom | Tilbakevendende voksent immunoblastisk storcellet lymfom | Perifert T-celle lymfom | Anaplastisk storcellet lymfom | Angioimmunoblastisk T-celle lymfom | Hepatosplenisk T-celle lymfom | Tilbakevendende voksen T-celle leukemi/lymfom | Tilbakevendende...Forente stater